FORMULIERUNG UND TABLETTEN MIT GUAIFENESIN MIT VERZÖGERTER FREISETZUNG
The invention relates to a modified release pharmaceutical product having two portions, wherein a first portion comprises a first quantity of guaifenesin and a first pharmaceutical additive in an immediate release formulation, wherein the first quantity of guaifenesin becomes fully bioavailable in t...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | DAVIS, ROBERT BLUME, RALPH KEYSER, DONALD |
| description | The invention relates to a modified release pharmaceutical product having two portions, wherein a first portion comprises a first quantity of guaifenesin and a first pharmaceutical additive in an immediate release formulation, wherein the first quantity of guaifenesin becomes fully bioavailable in the subject's stomach, and a second portion comprises a second quantity of guaifenesin and a second pharmaceutical additive in a sustained release formulation, wherein the ratio of said first quantity to said second quantity provides a C max in a human subject equivalent to the C max obtained when the first of three doses of a standard immediate release formulation having one third of a total amount of guaifenesin in the modified release product is dosed every four hours over a 12 hour period, wherein said product also provides therapeutically effective bioavailability for at least twelve hours after a single dose in a human subject according to serum analysis, and wherein the total amount of guaifenesin in the modified release product is from 600 mg to 1200 mg. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ATE391494TT1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ATE391494TT1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ATE391494TT13</originalsourceid><addsrcrecordid>eNrjZHB38w_yDfXxdA0K9XNXCPVzUQhxdPJxDQlx9VPw9QxRcA919HRz9XMN9oTww1yDog5Pc3cNCnENUnALcvUMdg2JAmrlYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxjiGuxpaGJpYmISGGxsSoAQCF8y6W</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FORMULIERUNG UND TABLETTEN MIT GUAIFENESIN MIT VERZÖGERTER FREISETZUNG</title><source>esp@cenet</source><creator>DAVIS, ROBERT ; BLUME, RALPH ; KEYSER, DONALD</creator><creatorcontrib>DAVIS, ROBERT ; BLUME, RALPH ; KEYSER, DONALD</creatorcontrib><description>The invention relates to a modified release pharmaceutical product having two portions, wherein a first portion comprises a first quantity of guaifenesin and a first pharmaceutical additive in an immediate release formulation, wherein the first quantity of guaifenesin becomes fully bioavailable in the subject's stomach, and a second portion comprises a second quantity of guaifenesin and a second pharmaceutical additive in a sustained release formulation, wherein the ratio of said first quantity to said second quantity provides a C max in a human subject equivalent to the C max obtained when the first of three doses of a standard immediate release formulation having one third of a total amount of guaifenesin in the modified release product is dosed every four hours over a 12 hour period, wherein said product also provides therapeutically effective bioavailability for at least twelve hours after a single dose in a human subject according to serum analysis, and wherein the total amount of guaifenesin in the modified release product is from 600 mg to 1200 mg.</description><language>ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2008</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20080415&DB=EPODOC&CC=AT&NR=E391494T1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20080415&DB=EPODOC&CC=AT&NR=E391494T1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DAVIS, ROBERT</creatorcontrib><creatorcontrib>BLUME, RALPH</creatorcontrib><creatorcontrib>KEYSER, DONALD</creatorcontrib><title>FORMULIERUNG UND TABLETTEN MIT GUAIFENESIN MIT VERZÖGERTER FREISETZUNG</title><description>The invention relates to a modified release pharmaceutical product having two portions, wherein a first portion comprises a first quantity of guaifenesin and a first pharmaceutical additive in an immediate release formulation, wherein the first quantity of guaifenesin becomes fully bioavailable in the subject's stomach, and a second portion comprises a second quantity of guaifenesin and a second pharmaceutical additive in a sustained release formulation, wherein the ratio of said first quantity to said second quantity provides a C max in a human subject equivalent to the C max obtained when the first of three doses of a standard immediate release formulation having one third of a total amount of guaifenesin in the modified release product is dosed every four hours over a 12 hour period, wherein said product also provides therapeutically effective bioavailability for at least twelve hours after a single dose in a human subject according to serum analysis, and wherein the total amount of guaifenesin in the modified release product is from 600 mg to 1200 mg.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2008</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHB38w_yDfXxdA0K9XNXCPVzUQhxdPJxDQlx9VPw9QxRcA919HRz9XMN9oTww1yDog5Pc3cNCnENUnALcvUMdg2JAmrlYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxjiGuxpaGJpYmISGGxsSoAQCF8y6W</recordid><startdate>20080415</startdate><enddate>20080415</enddate><creator>DAVIS, ROBERT</creator><creator>BLUME, RALPH</creator><creator>KEYSER, DONALD</creator><scope>EVB</scope></search><sort><creationdate>20080415</creationdate><title>FORMULIERUNG UND TABLETTEN MIT GUAIFENESIN MIT VERZÖGERTER FREISETZUNG</title><author>DAVIS, ROBERT ; BLUME, RALPH ; KEYSER, DONALD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ATE391494TT13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>ger</language><creationdate>2008</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>DAVIS, ROBERT</creatorcontrib><creatorcontrib>BLUME, RALPH</creatorcontrib><creatorcontrib>KEYSER, DONALD</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DAVIS, ROBERT</au><au>BLUME, RALPH</au><au>KEYSER, DONALD</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FORMULIERUNG UND TABLETTEN MIT GUAIFENESIN MIT VERZÖGERTER FREISETZUNG</title><date>2008-04-15</date><risdate>2008</risdate><abstract>The invention relates to a modified release pharmaceutical product having two portions, wherein a first portion comprises a first quantity of guaifenesin and a first pharmaceutical additive in an immediate release formulation, wherein the first quantity of guaifenesin becomes fully bioavailable in the subject's stomach, and a second portion comprises a second quantity of guaifenesin and a second pharmaceutical additive in a sustained release formulation, wherein the ratio of said first quantity to said second quantity provides a C max in a human subject equivalent to the C max obtained when the first of three doses of a standard immediate release formulation having one third of a total amount of guaifenesin in the modified release product is dosed every four hours over a 12 hour period, wherein said product also provides therapeutically effective bioavailability for at least twelve hours after a single dose in a human subject according to serum analysis, and wherein the total amount of guaifenesin in the modified release product is from 600 mg to 1200 mg.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | ger |
| recordid | cdi_epo_espacenet_ATE391494TT1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | FORMULIERUNG UND TABLETTEN MIT GUAIFENESIN MIT VERZÖGERTER FREISETZUNG |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T03%3A31%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DAVIS,%20ROBERT&rft.date=2008-04-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EATE391494TT1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |